Dr. Jack West reviews the preliminary clinical results on the IMpower150 trial that tested the value of adding the immune checkpoint inhibitor atezolizumab to carbo/paclitaxel/bevacizumab in patients with chemo-naïve advanced non-squamous NSCLC.
Atezolizumab in First Line NSCLC: Early Clinical Results from the IMpower150 Trial (BMIC-020)
